Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.
Here’s more on how proposed modifications to CMS’ Advance Notice Summary may affect reimbursement, payment growth rates, and regulation.
New analysis projects how MA plans would fare under new Part C benchmark formula.
According to a new report from the Oliver Wyman Actuarial Practice, MA organizations can expect a drop in revenue next year.
Recent exits indicate a fundamental miscalculation of the profile of the enrollees in the individual market. What’s next for the Exchanges?
Josh Sober, Tammy Tomczyk, and Amit Trivedi of Oliver Wyman’s Actuarial Health Practice break down MACRA’s impact on small practices.
Both practice transformation and capabilities development get a boost from new federal care and delivery model.
New joint replacement care guidance is pushing hospitals to examine their provider relationships and incentives.
